ERBB2 and neoplasm: These results imply that in mmBRCA(Her2) mice, where Her2 is genetically engineered to constitutively overexpress, additional activating mutations in the original copy of this gene may not confer significant growth advantages to tumor cells compared to functionally neutral mutations.